Shukra Pharmaceuticals Limited
BSE: SHUKRAPHAR · Pharmaceuticals
Snapshot
Unlock Shukra Pharmaceuticals Limited's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Shukra Pharmaceuticals Ltd. is an Ahmedabad-based company engaged in the manufacturing and marketing of a diverse range of pharmaceutical products. Its extensive portfolio encompasses various therapeutic categories, including antibiotics, anti-virals, analgesics, and corticosteroids, serving both domestic and international markets.
Business Model
The company generates revenue through the production and sale of a broad spectrum of pharmaceutical formulations. It operates as a manufacturer and marketer, distributing its medicinal products across diverse therapeutic segments.
- Incorporation Date:March 4, 1993
Growth Outlook
Growth is expected to be driven by the expansion of its wide-ranging pharmaceutical product portfolio and the continued penetration of both domestic and international markets.
Key Risks
- Regulatory Compliance. The company faces stringent regulatory oversight from health authorities, where non-compliance could lead to product recalls or manufacturing suspensions.
- Market Competition. The pharmaceutical sector is highly competitive, with numerous players exerting pressure on pricing and profit margins.
- Raw Material Price Volatility. Fluctuations in the cost of Active Pharmaceutical Ingredients (APIs) and other raw materials can significantly impact production costs and profitability.
- Geopolitical and Export Risks. Operating in international markets exposes the company to currency fluctuations, trade barriers, and varying regulatory standards across different countries.
Start your research today
Unlock AI insights, financials, peers and live data on Shukra Pharmaceuticals Limited and 5,000+ companies — free.
Key Metrics
REVENUE
₹75 Cr
TTM · standalone
NET PROFIT
₹40 Cr
TTM · standalone
EPS
₹0.90
TTM · standalone
RETURN ON EQUITY
51.7%
TTM · standalone
RETURN ON CAPITAL EMPLOYED
59.7%
TTM · standalone
P/E
68.7×
Q1 FY27 · standalone
EV/EBITDA
47.4x
Q1 FY27 · standalone
EBITDA MARGIN
70.3%
TTM · standalone
Peers · Pharmaceuticals
| Company | Mkt Cap | P/E (TTM) | EV/EBITDA | Rev Gr YoY | EBITDA Mgn | ROE | ROCE | 1Y Return |
|---|---|---|---|---|---|---|---|---|
Shukra Pharmaceuticals LimitedSHUKRAPHAR | ₹2,497 Cr | 68.7× | 47.43 | 115.0% | 70.3% | 51.7% | 59.7% | +75.8% |
Sakar HealthcareSAKAR | ₹2,587 Cr | 66.4× | 32.67 | 43.8% | 29.7% | 11.8% | 15.6% | +193.1% |
Beta Drugs LtdBETA | ₹2,425 Cr | — | — | — | 13.0% | — | — | +14.2% |
Panacea BiotecPANACEABIO | ₹2,338 Cr | -309.5× | 130.50 | 10.3% | 2.6% | -1.1% | -0.4% | -10.5% |
Indoco RemediesINDOCO | ₹2,318 Cr | 786.7× | 19.67 | 12.1% | 9.0% | 0.3% | 8.4% | -13.2% |
Fredun Pharmaceuticals LimitedFREDUN | ₹2,305 Cr | 16.3× | 22.33 | — | 14.9% | 20.9% | 39.1% | +2.0% |
As of Q1 FY27
Financials
Shukra Pharmaceuticals Limited
BSE: SHUKRAPHAR · Pharmaceuticals
Snapshot
Unlock Shukra Pharmaceuticals Limited's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Shukra Pharmaceuticals Ltd. is an Ahmedabad-based company engaged in the manufacturing and marketing of a diverse range of pharmaceutical products. Its extensive portfolio encompasses various therapeutic categories, including antibiotics, anti-virals, analgesics, and corticosteroids, serving both domestic and international markets.
Business Model
The company generates revenue through the production and sale of a broad spectrum of pharmaceutical formulations. It operates as a manufacturer and marketer, distributing its medicinal products across diverse therapeutic segments.
- Incorporation Date:March 4, 1993
Growth Outlook
Growth is expected to be driven by the expansion of its wide-ranging pharmaceutical product portfolio and the continued penetration of both domestic and international markets.
Key Risks
- Regulatory Compliance. The company faces stringent regulatory oversight from health authorities, where non-compliance could lead to product recalls or manufacturing suspensions.
- Market Competition. The pharmaceutical sector is highly competitive, with numerous players exerting pressure on pricing and profit margins.
- Raw Material Price Volatility. Fluctuations in the cost of Active Pharmaceutical Ingredients (APIs) and other raw materials can significantly impact production costs and profitability.
- Geopolitical and Export Risks. Operating in international markets exposes the company to currency fluctuations, trade barriers, and varying regulatory standards across different countries.
Start your research today
Unlock AI insights, financials, peers and live data on Shukra Pharmaceuticals Limited and 5,000+ companies — free.
Key Metrics
REVENUE
₹75 Cr
TTM · standalone
NET PROFIT
₹40 Cr
TTM · standalone
EPS
₹0.90
TTM · standalone
RETURN ON EQUITY
51.7%
TTM · standalone
RETURN ON CAPITAL EMPLOYED
59.7%
TTM · standalone
P/E
68.7x
Q1 FY27 · standalone
EV/EBITDA
47.4x
Q1 FY27 · standalone
EBITDA MARGIN
70.3%
TTM · standalone
Peers · Pharmaceuticals
As of Q1 FY27